Christopher J Pannucci1, Kory I Fleming2, Thomas K Varghese3, John Stringham3, Lyen C Huang4, T Bartley Pickron4, Ann Marie Prazak5, Corinne Bertolaccini5, Arash Momeni6. 1. Plastic Surgery Northwest, Spokane, WA. 2. Division of Plastic Surgery, University of Utah, Salt Lake City, Utah. 3. Division of Cardiothoracic Surgery, University of Utah, Salt Lake City, Utah. 4. Division of General Surgery, University of Utah, Salt Lake City, Utah. 5. Department of Pharmacy, University of Utah, Salt Lake City, Utah. 6. Division of Plastic Surgery, Stanford University, Palo Alto, California.
Abstract
OBJECTIVE: To examine the relationship between enoxaparin dose adequacy, quantified with anti-Factor Xa (aFXa) levels, and 90-day symptomatic venous thromboembolism (VTE) and post-operative bleeding. SUMMARY BACKGROUND DATA: Surgical patients often develop "breakthrough" VTE events-those which occur despite receiving chemical anticoagulation. We hypothesize that surgical patients with low aFXa levels will be more likely to develop 90-day VTE, and those with high aFXa will be more likely to bleed. METHODS: Pooled analysis of eight clinical trials (N = 985) from a single institution over a four year period. Patients had peak steady state aFXa levels in response to a known initial enoxaparin dose, and were followed for 90 days. Survival analysis log-rank test examined associations between aFXa level category and 90-day symptomatic VTE & bleeding. RESULTS: Among 985 patients, 2.3% (n = 23) had symptomatic 90-day VTE, 4.2% (n = 41) had 90-day clinically relevant bleeding, and 2.1% (n = 21) had major bleeding. Patients with initial low aFXa were significantly more likely to have 90-day VTE than patients with adequate or high aFXa (4.2% vs. 1.3%, p = 0.007). In a stratified analysis, this relationship was significant for patients who received twice daily (6.2% vs. 1.5%, p = 0.003), but not once daily (3.0% vs. 0.7%, p = 0.10) enoxaparin. No association was seen between high aFXa and 90-day clinically relevant bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18). CONCLUSIONS: This manuscript establishes inadequate enoxaparin dosing as a plausible mechanism for breakthrough VTE in surgical patients, and identifies anticoagulant dose adequacy as a novel target for process improvement measures.
OBJECTIVE: To examine the relationship between enoxaparin dose adequacy, quantified with anti-Factor Xa (aFXa) levels, and 90-day symptomatic venous thromboembolism (VTE) and post-operative bleeding. SUMMARY BACKGROUND DATA: Surgical patients often develop "breakthrough" VTE events-those which occur despite receiving chemical anticoagulation. We hypothesize that surgical patients with low aFXa levels will be more likely to develop 90-day VTE, and those with high aFXa will be more likely to bleed. METHODS: Pooled analysis of eight clinical trials (N = 985) from a single institution over a four year period. Patients had peak steady state aFXa levels in response to a known initial enoxaparin dose, and were followed for 90 days. Survival analysis log-rank test examined associations between aFXa level category and 90-day symptomatic VTE & bleeding. RESULTS: Among 985 patients, 2.3% (n = 23) had symptomatic 90-day VTE, 4.2% (n = 41) had 90-day clinically relevant bleeding, and 2.1% (n = 21) had major bleeding. Patients with initial low aFXa were significantly more likely to have 90-day VTE than patients with adequate or high aFXa (4.2% vs. 1.3%, p = 0.007). In a stratified analysis, this relationship was significant for patients who received twice daily (6.2% vs. 1.5%, p = 0.003), but not once daily (3.0% vs. 0.7%, p = 0.10) enoxaparin. No association was seen between high aFXa and 90-day clinically relevant bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p = 0.18). CONCLUSIONS: This manuscript establishes inadequate enoxaparin dosing as a plausible mechanism for breakthrough VTE in surgical patients, and identifies anticoagulant dose adequacy as a novel target for process improvement measures.
Authors: Janet E Baack Kukreja; Helen R Levey; Emil Scosyrev; Maureen Kiernan; Claudia Berrondo; Carrie McNamee; Guan Wu; Jean V Joseph; Ahmed Ghazi; Hani Rashid; Ann Dozier; Edward M Messing Journal: Urol Oncol Date: 2015-01-29 Impact factor: 3.498
Authors: Allison E Berndtson; Todd W Costantini; James Lane; Kevin Box; Raul Coimbra Journal: J Trauma Acute Care Surg Date: 2016-12 Impact factor: 3.313
Authors: Christopher J Pannucci; George Dreszer; Christine Fisher Wachtman; Steven H Bailey; Pamela R Portschy; Jennifer B Hamill; Keith M Hume; Ronald E Hoxworth; J Peter Rubin; Loree K Kalliainen; Andrea L Pusic; Edwin G Wilkins Journal: Plast Reconstr Surg Date: 2011-11 Impact factor: 4.730
Authors: Vinita Bahl; Andrew G Shuman; Hsou Mei Hu; Christopher R Jackson; Christopher J Pannucci; Cesar Alaniz; Douglas B Chepeha; Carol R Bradford Journal: JAMA Otolaryngol Head Neck Surg Date: 2014-11 Impact factor: 6.223
Authors: Tammy R Kopelman; Patrick J O'Neill; Paola G Pieri; Jeffrey P Salomone; Scott T Hall; Asia Quan; Jordan R Wells; Melissa S Pressman Journal: Am J Surg Date: 2013-10-22 Impact factor: 2.565
Authors: Elliott R Haut; Brandyn D Lau; Franca S Kraenzlin; Deborah B Hobson; Peggy S Kraus; Howard T Carolan; Adil H Haider; Christine G Holzmueller; David T Efron; Peter J Pronovost; Michael B Streiff Journal: Arch Surg Date: 2012-10